Since 2010, VivoSense has been helping clinical researchers analyze and interpret wearable sensor data to improve patient research and care. We are innovating within the pharmaceutical clinical trial industry by developing new digital biomarkers using our proprietary VivoSense® software.
The platform is designed to deliver real-world digital clinical measures from wearable sensors, which will help to advance patient-focused drug development and precision medicine for patients with cancer, Alzheimer’s, rare disease and other therapeutic indications. It allows rigorous interpretation of subtle shifts in human physiology through customized, body-worn monitoring and analysis solutions rooted in scientific foundations.
Our mission is to realize the potential of novel measures and technologies in regulatory and medical decision-making to leverage real-world data at scale, bringing life-saving treatments to the patients who need them most.
VivoSense closed a $25 Series A financing in March of 2022 to accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments (COAs). This financing will expand and refine our informatics platform for data analysis from wearable and connected technologies to deliver validated digital COAs for life science research.